PARABDRUGS

Parabolic Drugs Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Jun-2015.

Parabolic Drugs Limited, Parabolic Drugs Limited has submitted to the exchange the standalone & consolidated financial results along with the Auditors Report for the period ended 31-Mar-2015.

Price movement : Significant price movement has been observed in Parabolic Drugs Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Parabolic Drugs Limited has vide its letter inter-alia stated, "We have to submit that as on date, there exists no information as is required to be furnished to the Stock Exchange in terms of Clause 36 of the Listing Agreement."

Parabolic Drugs Limited has informed the Exchange that Mr. Balwan Bansal, Director, has resigned from the Board of Director of the Company w.e.f. February 12, 2015.

Parabolic Drugs Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 31-Dec-2014.

Parabolic Drugs Limited has informed the Exchange that the Board of Director in its Meeting held on February 14, 2015: 1. Appointed R.K. Bhalla & Associates, Practicing Company Secretary as Secretarial Auditor of the Company. 2. Took note of the Resignation of Mr. Balwan Bansal from the Board of Director of the Company.

Parabolic Drugs Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Sep-2014.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors in its meeting held on November 14, 2014: 1. Appointed Mrs. Vandana Singla, as an Independent Director of the Company.

Parabolic Drugs Limited has submitted to the Exchange a copy of Minutes of Annual General Meeting of the Company held on September 30, 2014.

Parabolic Drugs Limited has informed the Exchange regarding the Outcome of Annual General Meeting of the Company held on September 30, 2014.

Parabolic Drugs Limited has submitted to the Exchange a copy Report of the Scrutinizer on the voting conducted in respect of the resolutions set out in the Notice convening the Annual General Meeting of the Company held on September 30, 2014.

Parabolic Drugs Limited has submitted to the Exchange a copy of Declaration of Result & Consolidated Report of the Scrutinizer on the E-voting & Voting by Poll conducted in respect of Annual General Meeting of the Company held on September 30, 2014.

Parabolic Drugs Limited has informed the Exchange regarding the Outcome of Annual General Meeting of the Company held on September 30 , 2014.

Parabolic Drugs Limited has submitted to the Exchange a copy of the Notice of Annual General Meeting of the Company to be held on September 30, 2014.

Parabolic Drugs Limited has informed the Exchange that the voting rights of shareholders in respect of the items set out in the Notice of Annual General Meeting shall be in proportion to their shareholding in the paid up equity share capital of the Company as on the cut-off date (record date) which has been fixed as August 29, 2014.

Parabolic Drugs Limited has informed the Exchange that the Company has fixed Book Closure from September 27, 2014 to September 30, 2014 (both days inclusive) for the purpose of annual closing. Further, the Annual General Meeting of the Members of the Company will be held on September 30, 2014.

Parabolic Drugs Limited has informed the Exchange that 1. Mr.Jagjit Singh Chahal has been appointed as a Director on the Board of Directors of the Company w.e.f August 14, 2014. 2. Mr. Nikhil Goel, Director, has resigned from the Board of Directors of the Company w.e.f August 12, 2014.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors at its meeting held on August 14, 2014 has (1) Approved the Performa & Annexure to be submitted with Cost Auditor report for the Financial Year 2013-14.(2) Appointed Mr Jagit Singh Chahal as an Independent Director on the Board of Directors of the Company.(3) Took note of the resignation of Mr Nikhil Goel from the Board of Directors of the Company.(4) Reconstituted the Audit Committee, Nomination & Remuneration Committee and Stakeholders Relationship Committee of the Company.

Parabolic Drugs Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Jun-2014.

Parabolic Drugs Limited has informed the Exchange that Mr Balbir Singh Bhasin Nominee Director of State Bank of India (SBI) has resigned from the Board of Directors of the Company w.e.f. July 02, 2014.

Parabolic Infrastructure Private ltd has submitted to the Exchange vide letter dated July 09, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parabolic Infrastructure Private Ltd has submitted to the Exchange vide letter dated July 03, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parabolic Infrastructure Private Ltd has submitted to the Exchange vide letter dated June 24, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parabolic Infrastructure Private Limited has submitted to the Exchange, vide letter dated June 12, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 30, 2014, has:1. Recommended the reappointment of M/s. S. K. Bansal & Co., Chartered Accountants, Chandigarh, as Statutory Auditors, for the Financial Year 2014-15. 2. Approved the appointment of M/s. Anil Sharma & Co., Cost Accountants. Chandigarh, as Cost Auditors for the Financial Year 2014-15.

Parabolic Drugs Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Mar-2014.

Parabolic Drugs Limited has informed the Exchange that the Company has received European GMP Certifications for its:(1) Works Site located at Derabassi for manufacture of Cephalosporin products. (Certificate No. DE_RP_01_GMP_2014_0023).(2) Works Site located at Lalru for manufacture of Non-beta Lactams products. (Certificate No. DE_RP_01_GMP_2014_0024).

Parabolic Infrastructure Private Ltd has submitted to the Exchange vide letter dated May 19, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parabolic Infrastructure Private Ltd has submitted to the Exchange, vide letter dated April 30, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

SBICAP Trustee Company Limited has submitted to the Exchange vide letter dated April 29, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parabolic Infrastructure Private Ltd has submitted to the Exchange, vide letter dated April 17, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parabolic Infrastructure Private Ltd has submitted to the Exchange vide letter dated April 11, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parabolic Infrastructure Private Ltd has submitted to the Exchange vide letter dated March 20, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Rama Gupta has submitted to the Exchange vide letter dated March 10, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parabolic Infrastructure Private Ltd has submitted to the Exchange vide letter dated March 06, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 14, 2014 has authorised the Committee of Directors (Share Allotment) to make allotment of 92,00,000 equity shares of the Company of Rs. 10/- each at a premium of Rs. 4.40/- per share, as already approved by the Members of the Company through Postal Ballot to the proposed allottees i.e. M/s. Kenam Education Services (P) Ltd., M/s. Parabolic Infrastructure (P) Ltd., M/s. PNG Trading (P) Ltd., M/s. Trackball Technology (P) Ltd., Mrs. Rama Gupta, Mr. Vineet Gupta and Mr. Pra

Parabolic Drugs Limited has submitted to the exchange the standalone financial results for the period ended 31-Dec-2013.

Parabolic Drugs Limited has informed the Exchange regarding a result of postal ballot.

Parabolic Drugs Limited has submitted to the Exchange a copy of notice pursuant to Section 192A of the Companies Act, 1956 read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2011.

Parabolic Infrastructure Private Limited has submitted to the Exchange vide letter dated December 23, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parabolic Drugs Limited has submitted to the Exchange vide letter dated December 20, 2013 a copy of notice of postal ballot dated November 14, 2013.

Parabolic Infrastructure Private Limited has submitted to the Exchange vide letter dated December 20, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parabolic Drugs Limited has submitted to the exchange the standalone financial results for the period ended 30-sep-2013.

Parabolic Drugs Limited has informed the Exchange regarding the outcome of the Board Meeting of the Company held on November 14, 2013.

Parabolic Drugs Limited has informed the Exchange that the Annual General Meeting of the Company will be held on September 30, 2013. The Register of Members and the Share Transfer Books of the Company will remain closed from September 26, 2013 to September 30, 2013 (both days inclusive) for Annual Book Closure.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors of the Company in its meeting held on August 10, 2013 has: 1. Approved the resignation of Dr. Ram Kumar from the Directorship of the Company. 2. Approved the appointment of Mr. Balbir Singh Bhasin (a nominee of State Bank of India) on the Board of the Company. 3. Approved the reconstitution of Remuneration Committee and Investor's Grievance Committee of the Company. 4. Approved the re-appointment of Mr. Pranav Gupta as Managing Director and of Mr. Vineet Gupta as the Whole-Time Director of the Company.

Parabolic Drugs Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2013.

Parabolic Drugs Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2013.

Parabolic Drugs Limited has informed the Exchange regarding the update on the CDR Application filed by the Company.The Company has now informed the Exchange that Due to clerical error, the Company have mentioned September 30, 2013 as Cut Off date (COD) for CDR instead of September 30, 2012. Therefore, the Cut Off Date (COD) for CDR should be read as September 30, 2012 instead of September 30, 2013.

Parabolic Drugs Limited has informed the Exchange that the proposal of the Company for restructuring of its Debt has been approved by the Empowered Group of Corporate Debt Restructuring (CDR) Cell. Pursuant to the term and conditions of LOA, the Master Restructuring Agreement (MRA) has been executed between the Company and the Lenders on March 28, 2013. The cut of date for the CDR Package shall be September 30, 2013. The CDR package envisages reduction in rate of interest; re-schedulement of payment of interest and principal amount of working capital facilities and term loans.